logo
  

Victrex Q3 Revenue Flat, Sales Volume Rises 17% - Quick Facts

High performance polymer solutions provider Victrex Plc. (VCT.L) Tuesday said in a third-quarter trading update that it saw solid trading against tougher comparatives.

According to the company, its performance reflected continuing growth across industrial markets, which is offsetting sales to Oil & Gas and a lower contribution from its Invibio medical business.

Third-quarter group revenue was nearly flat with last year at 64.5 million pounds, and slightly ahead in constant currency.

Group sales volume increased 17 percent to 1,070 tonnes from 911 tonnes.

Victrex also announced the acquisition of Kleiss Gears, a US based polymer gears' manufacturer, for approximately $6 million in cash.

Kleiss has over 20 years' experience of unique design and precision moulding capability in gears. It will benefit from Victrex's materials know-how, existing customer relationships and global commercial reach.

Victrex said the acquisition is in line with its strategy of moving further downstream and investing in growth acceleration opportunities for its pipeline projects.

For its 2014 financial year, Kleiss had revenues of $4 million and employed 26 people.

For the year as a whole, despite challenges in the Oil & Gas market, Victrex said its overall momentum remains positive and it still expects to fully overcome the impact of foreign currency.

Consequently, and reflecting its balanced portfolio, Victrex said it remains well positioned to deliver profit progress over the full year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT